

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bauersachs Johann	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : ACS, heart Failure, Kidney disease (2016) - Boehringer-Ingelheim : Afib, Diabetes mellitus (2016) - Abiomed : CAD, cardigenic shock (2016) - Heartware : Heart Failure (2016) - Berlin Chemie AG : Hypertension, CAD (2016) - Daiichi Sankyo : ACS, Afib (2016-2017) - Bayer : Afib, heart failure (2016-2017) - Bristol Myers Squibb : Afib, heart failure (2016-2017) - Merck Sharp & Dohme : CAD, Hypercholesterolemia (2016-2017) - Medtronic : Heart Failure (2016-2017) - Servier : Heart Failure (2016-2017) - Thoratec/SJM : Heart Failure (2016-2017) - Pfizer : Heart Failure, Afib (2016-2017) - Biotronik : Heart Failure, CAD (2016-2017) - Novartis : Hypertension, Heart Failure (2016-2017) - Orion : Acute Heart Failure (2017) - Boehringer-Ingelheim : Afib, Diabetes mellitus, Heart Failure (2017) - CVRx : Heart Failure (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Vascular remodeling (2016)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bauersachs Johann	<ul style="list-style-type: none"> - Medtronic : CAD (2016-2017) - Abiomed : cardiogenic shock (2016-2017) - Zoll Medical : Arrhythmia (2017) - CVRx : Heart Failure (2017)
Blomstrom-Lundqvist Carina	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Biosense Webster : ablation (2016) - Atricure : AF ablation (2016) - Pfizer : anticoagulation (2016) - Boston Scientific : devices (2016) - Bayer : anticoagulation (2016-2017) - Sanofi Aventis : anticoagulation (2016-2017) - Merck Sharp & Dohme : anticoagulation (2016-2017) - Medtronic : devices (2016-2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : anticoagulation (2016) - Boston Scientific : Arrhythmia (2016) - Medtronic : AF (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : AF (2016-2017) - Cardiomems : drug (2016-2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Cifkova Renata	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Ferrer Internacional : cardiovascular (2016) - Merck Sharp & Dohme : cardiovascular (2016) - Amgen Czech republic : cardiovascular (2016)
De Bonis Michele	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Medtronic : valve prostheses (2016-2017)
Iung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016-2017) - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017)
Johnson Mark	<p>Nothing to be declared (2016-2017)</p>
Kintscher Ulrich	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulation (2016) - Sanofi Aventis : Dyslipidemia (2016)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kintscher Ulrich	<ul style="list-style-type: none"> - Sciarc GmbH : Heart failure (2016) - Berlin Chemie AG : Hypertension (2016-2017) - Novartis : Heart Failure (2017) - Bayer AG : Hypertension (2017) - CTI Congress Management : Hypertension (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : Heart Failure (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Bayer AG : Heart Failure (2016) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - German Hypertension League (2017)
Kranke Peter	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Acacia Ltd : Antiemetics (2016-2017) - Medtronic : Capnography (2016-2017) - FreseniusKabi : Infusion / Anaesthetics (2016-2017) - BBraun : Pain Management (2016-2017) - Gruenthal : Pain Management (2016-2017) - The Medicines Company : Pain medicine (2016-2017) - Ratiopharm : Vasopressors (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Acacia Ltd. : Antiemetics Phase III Trials (2016-2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Kranke Peter	- Ministry of Health, Bavaria (Germany) : Telemedicine / Critical Care (2016-2017)
Lang Irene Marthe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Menarini : coronary artery disease (2016) - Actelion : pulmonary hypertension (2016) - Bayer AG : pulmonary hypertension (2016) - AOPOrphan : pulmonary hypertension (2016) - Medtronic : vascular intervention (2016) - Kaneka : interventional devices (2017) - Medtronic : medical devices (2017) - Actelion : Pulmonary Hypertension medications (2017) - Ferrer Internacional : Pulmonary Hypertension medications (2017) - MSD : Pulmonary Hypertension medications (2017) - AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : heart failure (2016) - Actelion : Pulmonary Hypertension medications (2017) - AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Actelion : pulmonary hypertension (2016) - AOP Orphan Pharmaceuticals : pulmonary hypertension (2016) - Actelion : Pulmonary Hypertension medications (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lang Irene Marthe	- AOP Orphan Pharmaceuticals : Pulmonary Hypertension medications (2017)
Morais Joao	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Anticoagulants (2016) - Bayer Healthcare : Anticoagulants (2016) - Bristol Myers Squibb : Anticoagulants (2016) - Boehringer Ingelheim : Anticoagulants (2016) - Astra Zeneca : Antiplatelets (2016) - Merck Sharp & Dohme : Antiplatelets, lipids (2016) - Boston Scientific : Left Atrial Apendage Closure (2016) - Amgem : Lipids (2016) - Merck Sharp & Dohme : ATOZET (2017) - Boehringer-Ingelheim : Dabigatran (2017) - Novartis : Entresto (2017) - Servier : Ivanradina (2017) - Bial Portela : Lipids (2017) - Menarini : Ranolazina (2017) - Bayer Healthcare : Rivaroxaban (2017) - Astra Zeneca : Ticagrelor (2017)
Pieper Els Petronella G	Nothing to be declared (2016-2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Presbitero Patrizia	Nothing to be declared (2016-2017)
Price Susanna	<p>Nothing to be declared (2016)</p> <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring.</p> <ul style="list-style-type: none"> - Employed full-time by the UK National Health Service as a clinical consultant in intensive care and cardiology at the Royal Brompton Hospital (2017)
Regitz-Zagrosek Vera	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vinzenz von Paul Kliniken gGmbH : Hospital (2016) - Novartis : cardiovascular medicine (2017) - Berlin Chemie AG : cardiovascular medicine (2017) - Pfizer Pharma GmbH : cardiovascular medicine (2017) - Verband deutscher Unternehmerinnen : Gender medicine (2017) - Zahnmedizinisches Fortbildungszentrum : Gender medicine (2017) - Saarländischer Hausärzterverband : Gender medicine (2017) - Cognomed : Heart failure therapy (2017)
Roos-Hesselink Jolien W	Nothing to be declared (2016-2017)
Rosano Giuseppe M C	Nothing to be declared (2016-2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Task Force

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Seeland Ute	Nothing to be declared (2016-2017)
Swan Lorna	<p>1- Financial Declaration</p> <p style="padding-left: 20px;">D - Research funding (departmental or institutional) from healthcare industry. - British Heart Foundation : Grant funding to the ACHD Unit (2016-2017)</p> <p>2- Other Positions of Influence</p> <p style="padding-left: 20px;">2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - Member of the UK Clinical Reference Group (governmental organisation) for congenital heart disease. (2016)</p> <p style="padding-left: 20px;">2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Council member of the BCCA (British Congenital Cardiac Association) (2016)</p>
Tommaso Simoncini	<p>1- Financial Declaration</p> <p style="padding-left: 20px;">A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : Pregnancy (2016)</p> <p style="padding-left: 20px;">B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - SunMedical : Surgical devices for Pelvi organ prolapse treatment (2017) - Laborest : Urinary tract Infection (2017)</p>
Warnes Carole A	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p style="padding-left: 20px;">C - Receipt of royalties for intellectual property. - Book : general cardiology/congenital heart disease (2017)</p>

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Amgen : Hyperlipidemia (2017) - Novartis : Hypertension (2017) - Boehringer-Ingelheim : Oral anticoagulation (2017) - Bayer Healthcare : Oral anticoagulation (2017) - Pfizer/BMS alliance : Oral anticoagulation (2017)
Agewall Stefan	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Antiplatelet treatment (2017)
Banu Cristiana	Nothing to be declared (2017)
Barbato Emanuele	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boston Scientific : Education courses on rotational atherectomy (2017) - Abbott Vascular : Educational courses on FFR (2017) D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : Unrestricted grant for an investigator-driven study (2017)
Barysiene Jurate	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : antihypertensive treatment (2017) - Pfizer : Apixaban (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Barysiene Jurate	<ul style="list-style-type: none"> - Boehringer-Ingelheim : Dabigatran (2017) - Bayer : Rivaroxaban (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Apama Medical Inc. : electrophysiology, AF treatment (2017) - BackBeat Medical Inc. : electrophysiology, hypertension treatment (2017)
Benlamin Hisham	Nothing to be declared (2017)
Bertelli Luca	Nothing to be declared (2017)
Bouma Berto	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : mitralclip (2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Apixaban (2017) - Bristol Myers Squibb : Apixaban (2017) - Bayer : Aspirin, rivaroxaban (2017) - MEDSCAPE-the heart.org : Inespecific (2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) - Astra Zeneca : Ticagrelor (2017) - Ferrer Internacional : Trinomia (polypill) (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - BMS : CV013-011 - STANDUP-AHF trial (2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - VP elect. Spanish Society of Cardiology FAHA (2017)
Calda Pavel	Nothing to be declared (2017)
Caluk Jasmin	Nothing to be declared (2017)
Caruana Maryanne	Nothing to be declared (2017)
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Merck Serono : Bisoprolol-Amlodipine (2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2017) - Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2017) - Johnson & Johnson : antithrombotic (2017) - Bayer AG : antithrombotic (2017) - Sanofi Aventis : dyslipidemia (2017) - Fournier Laboratories : dyslipidemia (2017) - Amgen Inc : dyslipidemia , (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Novartis : HF (2017) - Vifor International : iron deficiency (2017) - Actelion : PHT (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2017) - Johnson & Johnson : antithrombotic (2017) - Bayer AG : antithrombotic (2017) - Sanofi Aventis : dyslipidemia (2017) - Amgen Inc : dyslipidemia (2017) - Fournier Laboratories : dyslipidemia (2017) - Novartis : HF (2017) - Vifor International : iron deficiency (2017) - Actelion : PHT (2017)
De Backer Julie	Nothing to be declared (2017)
Deaton Christi	<p>1- Financial Declaration</p> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - GlaxoSmithKline : COPD (patient media) (2017)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	D - Research funding (departmental or institutional) from healthcare industry. - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017) - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Di Salvo Giovanni	Nothing to be declared (2017)
Dubrava Juraj	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : idarucizumab, dabigatran (2017) - Servier : ivabradine (2017) - Bayer : rivaroxaban (2017) - Novartis : sacubitril/valsartan (2017)
Erwin John	Nothing to be declared (2017)
Estensen Mette-Elise	Nothing to be declared (2017)
Fitzsimmons Samantha	Nothing to be declared (2017)
Fitzsimons Donna	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Furenas Eva	Nothing to be declared (2017)
Gaemperli Oliver	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - GE Healthcare : Imaging (2017)
Garbi Madalina	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Edwards Lifesciences : Once only fee for participation to a group meeting regarding symptoms in aortic stenosis (2017)
Geraci Giovanna	Nothing to be declared (2017)
Gevaert Sofie	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : acute coronary syndromes (2017) - Novartis : heart failure (2017) - Merck Sharp & Dohme : heart failure, prevention (2017)
Giannakoulas George	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Menarini : Chronic coronary artery disease (2017) - Astra Zeneca : Coronary Artery Disease (2017) - Novartis : Heart Failure (2017) - Servier : Heart Failure-Chronic Coronary Artery Disease (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Giannakoulas George	<ul style="list-style-type: none"> - Mylan : Hyperlidaemia (2017) - Sanofi Aventis : Hyperlipidemia (2017) - MSD : Hyperlipidemia-Pulmonary Hypertension (2017) - Actelion : Pulmonary Hypertension (2017) - GlaxoSmithKline : Pulmonary Hypertension (2017) - Lilly : Pulmonary Hypertension (2017) - Elpen Pharmaceuticals : Pulmonary Hypertension (2017) - Bayer : Thromboembolic Disease (2017) - Boehringer-Ingelheim : Thromboembolic Disease (2017) - Pfizer : Thrombosis- Pulmonary Hypertension (2017)
Gotcheva Nina	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim, Sanofi, Actavis-Teva : Dabigatran, Alirocumab (2017)
Gratii Cristina	Nothing to be declared (2017)
Haddour Laila	Nothing to be declared (2017)
Hammoudi Naima	Nothing to be declared (2017)
Heracleous Hera	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott, Biotronik, Medtronic, Boston Scientific : Electrophysiology, arrhythmias (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
Hoffman Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : drugs (2017) - Actelion : Drugs (2017) - Sanofi Aventis : DRugs (2017) - Berlin Chemie AG : DRugs (2017) - Recordati International : drugs (2017) - Abbott : MitraCip (2017)
Ibrahimi Pranvera	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Jondeau Guillaume	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Novartis : heart failure (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Novartis : heart failure (2017)</p>
Juni Peter	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017)</p> <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)</p>
Kaaja Risto Juhani	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Sanofi Aventis : LMWH (2017) - Leo Pharma : LMWH (2017)</p>
Kadry Zeina	<p>Nothing to be declared (2017)</p>

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2017) - Astra Zeneca : Ticagrelor (2017) - Bayer Vital : Xarelto-NOAK (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2017) - Philips : MRT (2017)
Kiss Robert Gabor	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis steering committee member : coordination of a PCSK9 study (2017) - TIMI group steering committee member : diabetes drug therapy (2017) - Cleveland Clinic Research Foundation : fish oil (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : diabetes oral drugs (2017) - Pfizer : NOAC (2017) - Bayer AG : NOAC (2017) - Boehringer-Ingelheim : NOAC, empaglifozin (2017) - Amgen : PCSK9 inhibitor (2017) - MSD : sitagliptin, ezetimibe, edoxaban (2017)
Kluin Jolanda	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Knuuti Juhani	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017)
Kozelj Mirta	Nothing to be declared (2017)
Lancellotti Patrizio	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Ischemic Heart Disease (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer : NOAC (2017)
Leclercq Christophe	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Abbott : devices (2017) - Boston Scientific : devices (2017) - Medtronic : devices (2017) - Biotronik : devices (2017) - Livanova : devices (2017) D - Research funding (departmental or institutional) from healthcare industry. - Biotronik : devices (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lionis Christos	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Gilead : Advisory Board fees (topic relevant to vaccinations in adults) (2017) C - Receipt of royalties for intellectual property. - Olvos SA : Cretan lama (2017)
Lunegova Olga	Nothing to be declared (2017)
Mascherbauer Julia	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Pfizer : cardiac amyloidosis (2017) - AOP Orphan Pharmaceuticals : pulmonary hypertension (2017)
Maser Maarja	Nothing to be declared (2017)
McDonagh Theresa	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Vifor International : Ferrinject (2017) - Novartis : Honoraria (2017) - Bayer AG : Honoraria (2017)
Meier Pascal	2- Other Positions of Influence 2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology. - British medical journal editor British society of cardiology board member (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mintale Iveta	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : speaker fees (2017) - Servier : speaker fees (2017) - Berlin Chemie AG : speaker fees (2017) - Merck Serono : speaker fees (2017)
Mitchenko Olena	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sanofi Aventis : Dyslipidemia (2017)
Moiseeva Olga	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary hypertension (2017) - Actelion : Pulmonary hypertension (2017) - Bayer AG : Pulmonary hypertension (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Pfizer : Pulmonary hypertension (2017) - Actelion : Pulmonary hypertension (2017)
Moons Philip	<p>Nothing to be declared (2017)</p>

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Mounier Vehier Claire	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : consultancy (2017) - Merck Sharp & Dohme : consultancy and speaker (2017) - Novartis : speaker (2017) - Resmed : speaker (2017) - Novo-Nordisk : speaker (2017) - Abbott : Speaker fees (2017) - Astra Zeneca : speaker fees (2017) - Boehringer-Ingelheim : speaker fees (2017)
Mourali Mohamed Sami	Nothing to be declared (2017)
Nelson-Piercy Catherine	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - UCB : RHEUMATOLOGY - cimzia certulizumab (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - ALLIANCE PHARMA : ANTIEMETIC - diclestin (2017) - Sanofi Aventis : LMWH - clexane - enoxaparin (2017)
Ozer Necla	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Pantazis Antonios	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Reata Pharmaceuticals : MOXIe study - RTA 408 in the Treatment of Friedreich's Ataxia (2017)</p>
Pasquet Agnes A	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Actelion : pulmonary hypertension, received a registration for a congress (2017) - Servier : speaker fee for organisation of a congress and a paper on bipressil (published in 2017) (2017)</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Catholic university of Leuven , 1200 Brussels : cardiology cardiac valves disease (2017) - Bayer : unspecified research grant (2017) - Daiichi Sankyo : unspecified research grant (2017)</p> <p>E - Research funding (personal). - Catholic university of Leuven , 1200 Brussels : cardiology cardiac valves disease (2017)</p>
Petris Antoniu Octavian	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Angina (2017) - Pfizer : Apixaban Eliquis (2017) - Boehringer-Ingelheim : Dabigatran PRADAXA (2017) - Societatea Romana de Cardiologie : Electrocardiography for ICU nurses (2017) - Novart Pharma Services Romania SRL : Entresto (2017) - Servier : Heart failure (2017) - Astra Zeneca : Hypertension (2017) - Servier : Hypertension (2017)</p>

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Petris Antoniu Octavian	<ul style="list-style-type: none"> - S.C. Berlin-Chimie Menarini SRL : Hypertension (2017) - GTS Solutions SRL : Polypill (2017) - Astra Zeneca : Ticagrelor Brilique (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : International Registry to assess mEdical Practice with IOngitudinal obseRvation for Treatment of Heart Failure REPORT-HF (2017)
Piepoli Massimo Francesco	Nothing to be declared (2017)
Piruzyan Armen	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Hypertension, SIHD (2017) - Takeda Pharmaceuticals : Hypertension, Heart failure (2017) - Bayer : Rivaroxaban - NOACs (2017)
Ponikowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : anticoagulant, diabetes (2017) - Respicardia : devices (2017) - Novartis : heart failure (2017) - Cardiorentis : heart failure (2017) - Berlin Chemie AG : heart failure (2017) - Bayer Healthcare : heart failure (2017) - Vifor Pharma ltd : heart failure (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - CIBIEM : heart failure (2017) - Servier : heart failure, coronary artery disease (2017) - Amgen : heart failure, lipids (2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Respicardia : anticoagulant (2017) - BioControl : devices (2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - Novartis : heart failure (2017) - Bayer Healthcare : heart failure (2017) - CIBIEM : heart failure (2017) - National Institute of Health : heart failure (2017) - Servier : heart failure, coronary artery disease (2017) - Amgen : heart failure, lipids (2017) - European Union grant : heart failure, prevention (2017)
Porter Avital	Nothing to be declared (2017)
Prieto Arevalo Raquel	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Prystrom Andrei	Nothing to be declared (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : aortic stenosis (2017) - Menarini : CAD- hypertension (2017) - Novo-Nordisk : diabetes (2017) - Novartis : hypertension (2017) - Unipharma : hypertension-thrombosis (2017) - Abbott : lipids (2017) - Amgen : lipids (2017) - Sanofi Aventis : Lipids (2017) - Lilly : Lipids (2017) - Unilever : lipids (2017) - Merck Sharp & Dohme : lipids (2017) - Vianex : lipids (2017) - Galenica : Lipids (2017) - Teva Pharmaceutical Industries : lipids, hypertension (2017) - Bayer Healthcare : Thrombosis (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Rocca Bianca	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer AG : Aspirin, Rivaroxaban (2017)</p> <p>E - Research funding (personal). - Italian Medicines Agency (AIFA) : aspirin (2017)</p> <p>2- Other Positions of Influence</p> <p>2.2 - Employment in healthcare industry (including part time) during the year for which you are declaring. - NA (2017)</p>
Roffi Marco	<p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry. - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)</p>
Rosenkranz Stephan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - BMS : Anticoagulation (2017) - Vifor International : heart failure (2017) - MSD : heart failure, pulmonary hypertension (2017) - Actelion : Pulmonary Hypertension (2017) - United Therapeutics : Pulmonary Hypertension (2017) - Arena Pharmaceuticals : pulmonary hypertension (2017)</p>

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Rosenkranz Stephan	<ul style="list-style-type: none"> - Pfizer : Pulmonary Hypertension, Anticoagulants (2017) - Novartis : Pulmonary Hypertension, Heart Failure (2017) - Bayer : Pulmonary Hypertension, Heart Failure, Anticoagulants (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : Steering committee member (2017) - Bayer : Steering Committee member (2017) - Actelion : Steering Committee member (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : Pulmonary Hypertension (2017) - Actelion : Pulmonary Hypertension (2017) - United Therapeutics : Pulmonary Hypertension (2017) - Novartis : Pulmonary Hypertension, Heart Failure (2017)
Rybak Karin	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer Healthcare : Anticoagulants (NOAKs) (2017) - Vifor International : Heart Failure (2017) - Medtronic : ICD, CRT, pacemaker (2017) - Astra Zeneca : Ticagrelor / Coronary heart disease (2017)
Samadov Fuad	<p>Nothing to be declared (2017)</p>

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Sarkozy Andrea	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Biosense Webster : Electrophysiology (2017)
Schwermann Markus	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Actelion : Pulmonary Hypertension (2017) - Merck Sharp & Dohme : Pulmonary Hypertension (2017) - Orpha Suisse : Pulmonary Hypertension (2017) D - Research funding (departmental or institutional) from healthcare industry. - Swiss National Science Foundation : Adult Congenital Heart Disease (2017) - Actelion : Pulmonary Hypertension (2017)
Shlyakhto Evgeny	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Krka Pharma : Arterial Hypertension (2017) - Novartis : Arterial Hypertension, Heart Failure (2017) - Merck Sharp & Dohme : Atherosclerosis (2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2017) - Pfizer : General Cardiology (2017)
Silversides Candice	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Simpson Iain A	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2017)
Skoric Bosko	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Novartis : Entresto (2017)
Sliwa-Hahnle Karen	Nothing to be declared (2017)
Sousa Uva Miguel	Nothing to be declared (2017)
Srbinovska-Kostovska Elizabeta	Nothing to be declared (2017)
Tamargo Juan Luis	1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Menarini : Angina, diabetes (2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Servier : Committee Member (2017) - Ferrer Internacional : Polypill (2017)
Thorne Sara	1- Financial Declaration C - Receipt of royalties for intellectual property. - Oxford University Press : Book (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Thrainsdottir Inga Sigurros	Nothing to be declared (2017)
Vakhtangadze Tamar	Nothing to be declared (2017)
Van De Velde Marc	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Janssen-Cilag : Anesthetics (2017) - Smiths Medical : Epidural and peripheral nerve blocks and pumps (2017) - Heron : Experimental drug for analgesia (2017) - Sintetica : Local Anesthetics (2017) - Nordic Pharma : Local anesthetics and coagulation drugs (2017) - MSD : Muscle relaxants and reversal agents (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Baxter : IV Fluids (2017) - Air liquide : Xenon (2017)
Vejlstrup Niels	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Biosense Webster : intracardiac ultrasound (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : intracardiac ultrasound (2017)
Vujisic-Tesic Bosiljka	Nothing to be declared (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Williams Bryan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Hypertension (2017) - Daiichi Sankyo : Hypertension (2017) - Novartis : Hypertension (2017) - Servier : Hypertension (2017) - Vascular Dynamics Inc, USA : Hypertension - device based therapy (2017) - Pfizer : Hypertension and cardiovascular risk management (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - Trustee of BP UK - a patient's association (2017)
Windecker Stephan	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : General Cardiology (2017) - Boston Scientific : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017)

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Bayer : afib (2017) - Pfizer : Afib (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Amgen : Hyperlipidemia (2016-2017) - Novartis : Hypertension (2016-2017) - Boehringer-Ingelheim : Oral anticoagulation (2016-2017) - Bayer Healthcare : Oral anticoagulation (2016-2017) - Pfizer/BMS alliance : Oral anticoagulation (2016-2017)
Agewall Stefan	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Antiplatelet treatment (2016-2017)
Barbato Emanuele	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Educational courses on FFR (2016) - Boston Scientific : Education courses on rotational atherectomy (2016-2017) - Abbott Vascular : Educational courses on FFR (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Unrestricted grant for an investigator-driven study (2016-2017)
Bueno Hector	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott : BVS (2016) - Servier : ivabradine (2016) - Novartis : Serelaxin, ACZ885, AHF Academy (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> - Pfizer : Apixaban (2016-2017) - Bristol Myers Squibb : Apixaban (2016-2017) - Bayer : Aspirin, rivaroxaban (2016-2017) - MEDSCAPE-the heart.org : Inespecific (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Ferrer Internacional : Trinomia (polypill) (2016-2017) - Sanofi Aventis : PCSK9 inhibitors (2017) - Novartis : Serelaxin, ACZ885, AHF Academy, (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Ticagrelor (2016-2017) <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> - Novartis : LCZ696 - PROMISE / PERSPECTIVE (2016) - BMS : CV013-011 - STANDUP-AHF trial (2016-2017) - Janssen-Cilag : Rivaroxaban - GEMINI ACS Trials 1 & 2 (2016-2017) - Astra Zeneca : Ticagrelor - EPICOR Study, THEMIS trial (2016-2017) - Novartis : LCZ696 - PROMISE trial / PERSPECTIVE trial / PREFER Study (2017) <p>2- Other Positions of Influence</p> <p>2.3 - Membership or affiliation in political or advocacy groups working in the field of cardiology.</p> <ul style="list-style-type: none"> - FAHA (2016) - VP elect. Spanish Society of Cardiology FAHA (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coca Antonio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boehringer-Ingelheim : Telmisartan; Telmisartan-Amlodipine; Telmisartan-HCTZ (2016) - Merck Serono : Bisoprolol-Amlodipine (2016-2017) - Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2016-2017) - Ferrer Internacional : Torasemide; CardiIncode microchips; Polypill (2016-2017)
Collet Jean-Philippe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - BMS : apixaban (2016) - Sanofi Aventis : CLOPIDOGREL (2016) - Medtronic : corevalve (2016) - Eli Lilly : PRASUGREL (2016) - Astra-Zeneca : ticagrelor (2016) - MSD : VORAPAXAR (2016) - Bayer Healthcare : xarelto (2016) - Bristol Myers Squibb : Lecture fees representing 2000 euros for 2017. (2017) - Roche Diagnostics : Lecture fees representing 800 euros for 2017. (2017) - Bayer Healthcare : Speaker Fees for antiplatelet therapy. This represented 2000 euros in total for 2017. (2017) - Servier : SPEAKER FEES OF 1000 EUROS IN 2017 (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Bristol Myers Squibb : APIXABAN (2016) - Medtronic : COREVALVE (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Collet Jean-Philippe	<ul style="list-style-type: none"> - Stago : LABORATORY TEST (2016) - Eli Lilly : PRASUGREL (2016) - FEDERATION FRANCAISE DE CARDIOLOGIE : THROMBOSIS (2016) - ICAN : THROMBOSIS (2016) - Astra Zeneca : TICAGRELOR (2016) - Boston Scientific : ACADEMIC RESEARCH DONATION TO THE ACTION FOUNDATION (www.action-fonds.org) (2017) - Bayer AG : ACADEMIC RESEARCH FUNDINGS (ADRIFT TRIALS) to the action study group (www.action-fonds.org) (2017) - Astra Zeneca : ACADEMIC RESEARCH FUNDINGS (ALPHEUS TRIAL) to the action study group (www.action-fonds.org) (2017) - Medtronic : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017) - Bristol Myers Squibb and Pfizer : Research fundings for Academic studies (atlantis trial) to the action study group (www.action-coeur.org) (2017)
Coman Ioan Mircea	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia , (2016-2017) - Novartis : HF (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Coman Ioan Mircea	<ul style="list-style-type: none"> - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : anticoagulants (2016-2017) - Johnson & Johnson : antithrombotic (2016-2017) - Bayer AG : antithrombotic (2016-2017) - Sanofi Aventis : dyslipidemia (2016-2017) - Amgen Inc : dyslipidemia (2016-2017) - Fournier Laboratories : dyslipidemia (2016-2017) - Novartis : HF (2016-2017) - Vifor International : iron deficiency (2016-2017) - Actelion : PHT (2016-2017)
Delgado Victoria	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : Mitraclip (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : Pacemaker-Heart failure (2016) - Medtronic : Pacemaker-Heart failure (2016) - Biotronik : Pacemaker-Heart Failure (2016) - Edwards Lifesciences : Valvular heart disease (2016) - Boston Scientific : pacemakers (2017) - Medtronic : pacemakers (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Delgado Victoria	<ul style="list-style-type: none"> - Biotronik : pacemakers (2017) - Edwards Lifesciences : valves (2017)
Fitzsimons Donna	Nothing to be declared (2016-2017)
Gaemperli Oliver	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - GE-Healthcare : Imaging (2016) - Amgen Inc : PCSK9 (2016) - Servier : Procorolan (2016) - GE Healthcare : Imaging (2017)
Hindricks Gerhard	<p>1- Financial Declaration</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Biotronik : CIEDs and interventional electrophysiology (2016) - Abbott : Pacemaker, Ablation (2017) - Biosense Webster : Pacemaker, Ablation (2017) - Biotronik : Pacemaker, catheter (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : CIEDs and interventional electrophysiology (2016) - St Jude Medical : CIEDs and interventional electrophysiology (2016) - Abbott, Biotronik, Medtronic, Boston Scientific : Electropysiology, arrhythmias (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - The Heart Center Leipzig / University Hospital for Cardiology, Cardiac Surgery and Pediatric Cardiology is part of the Helios Hospital Group. (2017)
lung Bernard	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Heart Valve Prostheses (2016-2017) - Boehringer Ingelheim : Anticoagulants (2017) - Novartis : Heart failure drugs (2017)
Juni Peter	<p>Nothing to be declared (2016)</p> <p>1- Financial Declaration</p> <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Anti-platelet Therapy (2017) - Biotronik : Drug-eluting stents (2017) - Biosensors International Group : Drug-eluting stents (2017) - The Medicines Company : Thrombin inhibitors (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Peter Jüni has received research grants to the institution from Astra Zeneca, Biotronik, Biosensors International, Eli Lilly and The Medicines Company, and serves as unpaid member of the steering group of trials funded by Astra Zeneca, Biotronik, Biosensors, St. Jude Medical and The Medicines Company. (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Katus Hugo	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Daiichi Sankyo : Lixiana_NOAK (2016-2017) - Astra Zeneca : Ticagrelor (2016-2017) - Bayer Vital : Xarelto-NOAK (2016-2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Biobank (2016-2017) - Philips : MRT (2016-2017)
Knuuti Juhani	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Astra Zeneca : Consultancy for a research project for ischemic heart disease (2017) - GE Healthcare : Consultancy for myocardial perfusion imaging agent (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Orion : Brain diseases (2016) - AC Immune : Brain diseases (2016) - Antaros : Endocrinology (2016) - Boehringer-Ingelheim : Neurology (2016) - MSD : Neurology (2016) - GE Gealthcare : Neurology (2016)
Lancellotti Patrizio	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - St Jude Medical : Echo course (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> - Servier : Ischemic Heart Disease (2016-2017) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Medtronic : Structural disease (2016) - Bayer : NOAC (2016-2017)
Leclercq Christophe	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Sorin Group : devices (2016) - St Jude Medical : devices (2016) - Bayer Healthcare : DOAC (2016) - Boston Scientific : devices (2016-2017) - Medtronic : devices (2016-2017) - Biotronik : devices (2016-2017) - Abbott : devices (2017) - Llvanova : devices (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Biotronik : devices (2017)
McDonagh Theresa	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Vifor International : Ferrinject (2016-2017) - Novartis : Honoraria (2016-2017) - Bayer AG : Honoraria (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>Nothing to be declared (2017)</p> <p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Servier : Committee member, Speaker fee (2016) - Novartis : Heart Failure Prevention Initiatives, Advisory Board (2016) - Amgen : Metabolic, Lipid (2016) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Novartis : Heart Failure Prevention Initiatives (2016)
Ponikowski Piotr	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Abbott Vascular : devices (2016) - BioControl : devices (2016) - Pfizer : lipids (2016) - Boehringer-Ingelheim : anticoagulant, diabetes (2016-2017) - Respicardia : devices (2016-2017) - Novartis : heart failure (2016-2017) - Cardiorentis : heart failure (2016-2017) - Berlin Chemie AG : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - Vifor Pharma ltd : heart failure (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Pfizer : lipids, heart failure (2017) <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - DC Device : devices (2016) - Cardioentis : heart failure (2016) - Respicardia : anticoagulant (2016-2017) - BioControl : devices (2016-2017) - Novartis : heart failure (2016-2017) - Bayer Healthcare : heart failure (2016-2017) - CIBIEM : heart failure (2016-2017) - Servier : heart failure, coronary artery disease (2016-2017) - Amgen : heart failure, lipids (2016-2017) - Cardionomic : devices (2017) - Impuls Dynamics : devices (2017) - National Institute of Health : heart failure (2017) - European Union grant : heart failure, prevention (2017)
Richter Dimitrios	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Angelini : Lipids (2016)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Richter Dimitrios	<ul style="list-style-type: none"> - Swisspharma : lipids-hypertension (2016) - Astra Zeneca : lipids-thrombosis (2016) - Pfizer : lipids-thrombosis (2016) - Winmedica : lipids-thrombosis (2016) - Boehringer-Ingelheim : thrombosis (2016) - Menarini : CAD- hypertension (2016-2017) - Novartis : hypertension (2016-2017) - Abbott : lipids (2016-2017) - Amgen : lipids (2016-2017) - Sanofi Aventis : Lipids (2016-2017) - Lilly : Lipids (2016-2017) - Unilever : lipids (2016-2017) - Merck Sharp & Dohme : lipids (2016-2017) - Vianex : lipids (2016-2017) - Galenica : Lipids (2016-2017) - Teva Pharmaceutical Industries : lipids, hypertension (2016-2017) - Bayer Healthcare : Thrombosis (2016-2017) - Edwards Lifesciences : aortic stenosis (2017) - Novo-Nordisk : diabetes (2017) - Unipharma : hypertension-thrombosis (2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Roffi Marco	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Terumo Inc : coronary catheters (2016) - Johnson & Johnson : coronary catheters (2016) - Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2016) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Boston Scientific : devices (2016) - Medtronic : devices (2016) - Biotronik : devices (2016) - Terumo Inc : devices (2016) - Abbott Vascular : devices (2016) - Boston Scientific : Stents (2017) - Medtronic : Stents (2017) - Biotronik : stents (2017) - Terumo Inc : stents (2017) - Abbott Vascular : stents (2017)
Shlyakhto Evgeny	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Krka Pharma : Arterial Hypertension (2016-2017) - Novartis : Arterial Hypertension, Heart Failure (2016-2017) - Merck Sharp & Dohme : Atherosclerosis (2016-2017) - Boehringer-Ingelheim : Dabigatran for Atrial Fibrillation (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Shlyakhto Evgeny	- Pfizer : General Cardiology (2016-2017)
Simpson Iain A	2- Other Positions of Influence 2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position. - Member and Past President of the British Cardiovascular Society Member of the Management Board of the American College of Cardiology National Cardiovascular Data Registries (2016-2017)
Sousa Uva Miguel	Nothing to be declared (2017) 1- Financial Declaration A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Boehringer-Ingelheim : Dabigatran (2016) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Astra Zeneca : Ticagrelor (2016)
Windecker Stephan	1- Financial Declaration B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry. - Bayer AG : General Cardiology (2017) - Abbott : Invasive Cardiology (2017) - Boston Scientific : Invasive Cardiology (2017) - Edwards Lifesciences : invasive Cardiology (2017) D - Research funding (departmental or institutional) from healthcare industry. - St Jude Medical : General Cardiology (2016) - Terumo Inc : General Cardiology (2016) - Bracco Pharmaceutical : General Cardiology (2016) - Boston Scientific : General Cardiology (2016-2017)

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts during the yearly call for declaration conducted every January covering the previous calendar year. The calls for declaration are conducted during the period of development of these guidelines up to and including 2017.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> - Abbott : General Cardiology (2017) - St. Jude Medical : General Cardiology (2017) - Amgen Inc. : General Cardiology (2017) - Symetis SA : Invasive Cardiology (2017) - Biotronik : Invasive Cardiology (2017) - Terumo Inc : Invasive Cardiology (2017) <p>2- Other Positions of Influence</p> <p>2.4 - Any other interest (financial or otherwise) that should be declared in view of holding an ESC position.</p> <ul style="list-style-type: none"> - Deputy Editor JACC CV Interventions Section Editor Uptodate Board Member SITEM (Swiss Institute of Translational and Entrepreneur Medicine) Advisor ECRI (European Cardiovascular Research Institute) Course Director, PCR (2017)
Zamorano Gomez Jose Luis	<p>1- Financial Declaration</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. from healthcare industry.</p> <ul style="list-style-type: none"> - Philips : 3D Echocardiography. (2016) - Servier : Clinical case presentation during ESC Cong 2016 (2016) - Pfizer : speaker CV risk factors. (2016) - MSD : speaker. CV risk factors (2016) - Bayer : afib (2017) - Pfizer : Afib (2017) <p>D - Research funding (departmental or institutional) from healthcare industry.</p> <ul style="list-style-type: none"> - Edwards Lifesciences : Echo for TAVi assessment & Epidemiology of Ao stenosis (2016) - Abbott : Epidemiology study of Mitral regurgitation (2016)